The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg Cramps
StudySetGo · NCT07651514
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 50
- US sites recruiting
- 7
- Study start
- October 10, 2026
- Record last updated
- October 26, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Participants are being invited to take part in a research study. Before deciding whether to take part, it is important for participants to understand why the research is being done and what it will involve.
Purpose: This study will investigate whether a multi-ingredient nutritional supplement containing magnesium and melatonin can improve sleep quality in adults who experience disrupted sleep due to nighttime leg cramps.
What participation involves: Participation lasts 8 weeks. Participants will be randomly assigned to take either the nutritional supplement or a placebo (inactive look-alike) every night before bed for 6 weeks. Participants will wear an Oura Ring wearable device on one finger continuously for 8 weeks throughout the study and complete short questionnaires using a smartphone app. The Oura Ring and study supplement will be sent to the participant's home address. Participants will never need to travel to a research centre; all contact with the research team will be by video call, phone, messaging, or email.
How long: Total involvement will be 8 weeks, made up of a 2-week baseline period and a 6-week supplementation period. Each day, participants will complete a short app-based questionnaire (approximately 1 minute). At the end of weeks 2, 4, 6, and 8, participants will complete additional app-based questionnaires (approximately 10 minutes).
Being studied: Magnesium and melatonin based multi-ingredient dietary supplementation; Placebo
Conditions: Poor Sleep Quality; Leg Cramps, Nocturnal
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adults aged 40-75 years
- Self-reported poor sleep quality (PSQI >5) at screening
- Self-reported nocturnal leg cramp averaging ≥4 episodes per fortnight at screening
- Capacity to understand and provide electronic informed consent
- Willing to wear an Oura Ring wearable device continuously throughout the study period
- Access to a smartphone/tablet with iOS 15 or higher and Android 9 or higher and willing to install and use the Oura and Trialflare applications
- Be a resident of and permanently living in Florida with no planned travel across more than one time zone for at least 1 night during the study period
Exclusion Criteria
- Current or recent (within 4 weeks of randomisation) use of melatonin, magnesium, or other supplements specifically taken for sleep or leg cramps or listed as an ingredient of the intervention supplement.
- Current use of any prescription medication
- Diagnosed sleep disorder (e.g. obstructive sleep apnoea, restless legs syndrome, insomnia disorder)
- Known or suspected secondary cause of nocturnal leg cramps (e.g. peripheral vascular disease, neurological condition, renal impairment, thyroid disorder)
- Any current or prior diagnosis of:
- Cancer or malignancy of any kind (prior malignancy is not exclusionary if the participant is in confirmed remission and has completed all treatment)
- Cardiovascular disease (e.g. hypertension, coronary artery disease, heart failure, arrhythmia, stroke, peripheral vascular disease)
- Autoimmune disorder (e.g. rheumatoid arthritis, lupus, multiple sclerosis)
- Gastrointestinal disorder (e.g. IBS, malabsorption syndromes)
- Neurological disorder (e.g. epilepsy, Parkinson's disease, dementia)
- Hepatic or renal impairment
- Diabetes mellitus (type 1 or type 2)
- Severe psychiatric disorder (e.g. schizophrenia, bipolar disorder)
- Myasthenia Gravis
- Known hypersensitivity or allergy to any ingredient in the active or placebo product
- Rotating shift work or irregular sleep patterns
- Current participation in another interventional clinical trial
- Inability to comply with study procedures or remote visit schedule
- Breastfeeding, pregnant, or planning to become pregnant during the study period
Recruiting US locations
StudySetGo - Decentralised (Remote) Site
Birmingham, AL 35203
Site contact: Christopher Koscien, PhD · 8886119860 · misit@studysetgo.com
StudySetGo - Decentralised (Remote) Site
Little Rock, AR 72201
Site contact: Christopher Koscien, PhD · 8886119860 · misit@studysetgo.com
StudySetGo Decentralised team
Palm Beach Gardens, FL 33418
Site contact: Tom Jameson · +44 7794865520 · tom.jameson@studysetgo.com
StudySetGo - Decentralised (Remote) Site
Atlanta, GA 30303
Site contact: Christopher Koscien, PhD · 8886119860 · misit@studysetgo.com
StudySetGo - Decentralised (Remote) Site
Charlotte, NC 28202
Site contact: Christopher Koscien, PhD · 8886119860 · misit@studysetgo.com
StudySetGo - Decentralised (Remote) Site
Charleston, SC 29401
Site contact: Christopher Koscien, PhD · 8886119860 · misit@studysetgo.com
StudySetGo - Decentralised (Remote) Site
Nashville, TN 37201
Site contact: Christopher Koscien, PhD · 8886119860 · misit@studysetgo.com
Study contacts (from the official record)
- Christopher Koscien, PhD · +447847617414 · misit@studysetgo.com
- Tom Jameson, PhD · +447794865520 · tom.jameson@studysetgo.com
Similar studies in Alabama
All sleep studies in Alabama →- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Cullman, AL + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Cullman, AL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
Jazz Pharmaceuticals
- Location
- Birmingham, AL + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70